Consensus for Radiotherapy in Hepatocellular Carcinoma from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials

Hee Chul Park, Jeong Il Yu, Jason Chia Hsien Cheng, Zhao Chong Zeng, Ji Hong Hong, Michael Lian Chek Wang, Mi Sook Kim, Kwan Hwa Chi, Po Ching Liang, Rheun Chuan Lee, Wan Yee Lau, Kwang Hyub Han, Pierce Kah Hoe Chow, Jinsil Seong

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

A consensus meeting to develop practice guidelines and to recommend future clinical trials for radiation therapy (RT), including external beam RT (EBRT), and selective internal RT (SIRT) in hepatocellular carcinoma (HCC) was held at the 5th annual meeting of the Asia-Pacific Primary Liver Cancer Expert consortium. Although there is no randomized phase III trial evidence, the efficacy and safety of RT in HCC has been shown by prospective and retrospective studies using modern RT techniques. Based on these results, the committee came to a consensus on the utility and efficacy of RT in the management of HCC according to each disease stage as follows: in early and intermediate stage HCC, if standard treatment is not compatible, RT, including EBRT and SIRT can be considered. In locally advanced stage HCC, combined EBRT with transarterial chemoembolization or hepatic arterial infusion chemotherapy, and SIRT can be considered. In terminal stage HCC, EBRT can be considered for palliation of symptoms and reduction of morbidity caused by the primary tumor or its metastases. Despite the currently reported benefits of RT in HCC, the committee agreed that there is a compelling need for large prospective studies, including randomized phase III trial evidence evaluating the role of RT. Specifically studies evaluating the efficacy and safety of sequential combination of EBRT and SIRT are strongly recommended.

Original languageEnglish
Pages (from-to)162-174
Number of pages13
JournalLiver Cancer
Volume5
Issue number3
DOIs
Publication statusPublished - 2016 Jul 1

Fingerprint

Liver Neoplasms
Hepatocellular Carcinoma
Radiotherapy
Clinical Trials
Prospective Studies
Safety
Practice Guidelines
Retrospective Studies
Neoplasm Metastasis
Morbidity
Drug Therapy
Liver

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Oncology

Cite this

Park, Hee Chul ; Yu, Jeong Il ; Cheng, Jason Chia Hsien ; Zeng, Zhao Chong ; Hong, Ji Hong ; Wang, Michael Lian Chek ; Kim, Mi Sook ; Chi, Kwan Hwa ; Liang, Po Ching ; Lee, Rheun Chuan ; Lau, Wan Yee ; Han, Kwang Hyub ; Chow, Pierce Kah Hoe ; Seong, Jinsil. / Consensus for Radiotherapy in Hepatocellular Carcinoma from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014) : Current Practice and Future Clinical Trials. In: Liver Cancer. 2016 ; Vol. 5, No. 3. pp. 162-174.
@article{097f38a0027848659076d54c8fd181ea,
title = "Consensus for Radiotherapy in Hepatocellular Carcinoma from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials",
abstract = "A consensus meeting to develop practice guidelines and to recommend future clinical trials for radiation therapy (RT), including external beam RT (EBRT), and selective internal RT (SIRT) in hepatocellular carcinoma (HCC) was held at the 5th annual meeting of the Asia-Pacific Primary Liver Cancer Expert consortium. Although there is no randomized phase III trial evidence, the efficacy and safety of RT in HCC has been shown by prospective and retrospective studies using modern RT techniques. Based on these results, the committee came to a consensus on the utility and efficacy of RT in the management of HCC according to each disease stage as follows: in early and intermediate stage HCC, if standard treatment is not compatible, RT, including EBRT and SIRT can be considered. In locally advanced stage HCC, combined EBRT with transarterial chemoembolization or hepatic arterial infusion chemotherapy, and SIRT can be considered. In terminal stage HCC, EBRT can be considered for palliation of symptoms and reduction of morbidity caused by the primary tumor or its metastases. Despite the currently reported benefits of RT in HCC, the committee agreed that there is a compelling need for large prospective studies, including randomized phase III trial evidence evaluating the role of RT. Specifically studies evaluating the efficacy and safety of sequential combination of EBRT and SIRT are strongly recommended.",
author = "Park, {Hee Chul} and Yu, {Jeong Il} and Cheng, {Jason Chia Hsien} and Zeng, {Zhao Chong} and Hong, {Ji Hong} and Wang, {Michael Lian Chek} and Kim, {Mi Sook} and Chi, {Kwan Hwa} and Liang, {Po Ching} and Lee, {Rheun Chuan} and Lau, {Wan Yee} and Han, {Kwang Hyub} and Chow, {Pierce Kah Hoe} and Jinsil Seong",
year = "2016",
month = "7",
day = "1",
doi = "10.1159/000367766",
language = "English",
volume = "5",
pages = "162--174",
journal = "Liver Cancer",
issn = "2235-1795",
publisher = "S. Karger AG",
number = "3",

}

Consensus for Radiotherapy in Hepatocellular Carcinoma from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014) : Current Practice and Future Clinical Trials. / Park, Hee Chul; Yu, Jeong Il; Cheng, Jason Chia Hsien; Zeng, Zhao Chong; Hong, Ji Hong; Wang, Michael Lian Chek; Kim, Mi Sook; Chi, Kwan Hwa; Liang, Po Ching; Lee, Rheun Chuan; Lau, Wan Yee; Han, Kwang Hyub; Chow, Pierce Kah Hoe; Seong, Jinsil.

In: Liver Cancer, Vol. 5, No. 3, 01.07.2016, p. 162-174.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Consensus for Radiotherapy in Hepatocellular Carcinoma from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014)

T2 - Current Practice and Future Clinical Trials

AU - Park, Hee Chul

AU - Yu, Jeong Il

AU - Cheng, Jason Chia Hsien

AU - Zeng, Zhao Chong

AU - Hong, Ji Hong

AU - Wang, Michael Lian Chek

AU - Kim, Mi Sook

AU - Chi, Kwan Hwa

AU - Liang, Po Ching

AU - Lee, Rheun Chuan

AU - Lau, Wan Yee

AU - Han, Kwang Hyub

AU - Chow, Pierce Kah Hoe

AU - Seong, Jinsil

PY - 2016/7/1

Y1 - 2016/7/1

N2 - A consensus meeting to develop practice guidelines and to recommend future clinical trials for radiation therapy (RT), including external beam RT (EBRT), and selective internal RT (SIRT) in hepatocellular carcinoma (HCC) was held at the 5th annual meeting of the Asia-Pacific Primary Liver Cancer Expert consortium. Although there is no randomized phase III trial evidence, the efficacy and safety of RT in HCC has been shown by prospective and retrospective studies using modern RT techniques. Based on these results, the committee came to a consensus on the utility and efficacy of RT in the management of HCC according to each disease stage as follows: in early and intermediate stage HCC, if standard treatment is not compatible, RT, including EBRT and SIRT can be considered. In locally advanced stage HCC, combined EBRT with transarterial chemoembolization or hepatic arterial infusion chemotherapy, and SIRT can be considered. In terminal stage HCC, EBRT can be considered for palliation of symptoms and reduction of morbidity caused by the primary tumor or its metastases. Despite the currently reported benefits of RT in HCC, the committee agreed that there is a compelling need for large prospective studies, including randomized phase III trial evidence evaluating the role of RT. Specifically studies evaluating the efficacy and safety of sequential combination of EBRT and SIRT are strongly recommended.

AB - A consensus meeting to develop practice guidelines and to recommend future clinical trials for radiation therapy (RT), including external beam RT (EBRT), and selective internal RT (SIRT) in hepatocellular carcinoma (HCC) was held at the 5th annual meeting of the Asia-Pacific Primary Liver Cancer Expert consortium. Although there is no randomized phase III trial evidence, the efficacy and safety of RT in HCC has been shown by prospective and retrospective studies using modern RT techniques. Based on these results, the committee came to a consensus on the utility and efficacy of RT in the management of HCC according to each disease stage as follows: in early and intermediate stage HCC, if standard treatment is not compatible, RT, including EBRT and SIRT can be considered. In locally advanced stage HCC, combined EBRT with transarterial chemoembolization or hepatic arterial infusion chemotherapy, and SIRT can be considered. In terminal stage HCC, EBRT can be considered for palliation of symptoms and reduction of morbidity caused by the primary tumor or its metastases. Despite the currently reported benefits of RT in HCC, the committee agreed that there is a compelling need for large prospective studies, including randomized phase III trial evidence evaluating the role of RT. Specifically studies evaluating the efficacy and safety of sequential combination of EBRT and SIRT are strongly recommended.

UR - http://www.scopus.com/inward/record.url?scp=84991004062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991004062&partnerID=8YFLogxK

U2 - 10.1159/000367766

DO - 10.1159/000367766

M3 - Review article

AN - SCOPUS:84991004062

VL - 5

SP - 162

EP - 174

JO - Liver Cancer

JF - Liver Cancer

SN - 2235-1795

IS - 3

ER -